BioVentrix raises $12M for heart attack treatment | MassDevice.com On Call

BioVentrix reports a $12.4 million funding round for its Revivent myocardial anchoring treatment for heart failure.

MASSDEVICE ON CALL — BioVentrix reported a $12.4 million funding round for its Revivent heart failure treatment.

San Ramon, Calif.-based BioVentrix said in an equity filing that the equity round, involving 195 unnamed investors, began Jan. 24 and closed today.

BioVentrix, MB Innovations, MicroPort Scientific, ReShape Medical, Spinal Solutions

News Well, On Call

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1xR5Wey